drugset / Trial / NCT02221960
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.
Timeline
- Start
- 2014-09-15
- Primary completion
- 2017-07-03
- Completion
- 2017-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | EFIZONERIMOD ALFA | Unknown | — | — |
Indications
No indication recorded.